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Dabigatran etexilate is a novel, oral, reversible, direct thrombin inhibitor that constitutes a major breakthrough for stroke
prevention in patients with nonvalvular atrial fibrillation (AF). Dabigatran was the first new oral anticoagulant approved in Europe
and became available in Portugal, for stroke prevention in nonvalvular AF, earlier than in most European countries. This paper is
the joint effort of a panel of experts from different specialties and provides information on the use of dabigatran, in anticipation
of the challenges that will come with increased usage.
1. Introduction
Dabigatran etexilate (designated as dabigatran from here
onwards) and other new oral anticoagulants (OACs) consti-
tute a major breakthrough for stroke prevention in patients
with nonvalvular atrial fibrillation (AF). They have been
shown to be an alternative to vitamin K antagonists (VKAs)
that does not require routine laboratory control. Dabigatran
(Pradaxa, Boehringer Ingelheim, Ingelheim, Germany) is
a reversible direct thrombin inhibitor and, in the RE-LY
trial (Randomized Evaluation of Long-term anticoagulation
therapY), a phase III study, 150 mg bid was more effective
in terms of stroke prevention in nonvalvular AF than VKA,
whereas 110 mg bid was as effective as VKA, with a lower
risk of bleeding [1]. Soon after the completion of this trial,
the US Food and Drug Administration (FDA) approved
dabigatran 150 mg bid and 75 mg bid (for patients with a
creatinine clearance of 15 to 30 mL/min) [2]. Subsequently,
the European Medicines Agency approved the doses of
150 mg bid and 110 mg bid (for patients aged at least 80 years,
with an elevated risk of bleeding or receiving verapamil)
[3] as an alternative to warfarin for stroke and systemic
embolism (SE) reduction in patients with nonvalvular
AF. The American College of Chest Physicians (ACCP)
Guidelines on Antithrombotic Therapy and Prevention of
Thrombosis (9th ed) suggest dabigatran 150 mg twice daily
rather than adjusted-dose VKA for patients with nonvalvular
AF [4]. Moreover, recent quantitative benefit-harm and
economic analyses in the UK support regulatory decisions
that dabigatran offers a positive benefit to harm ratio when
compared to warfarin [5].
Despite considerable variation among different coun-
tries, stroke has been appointed as the second leading cause
of death worldwide [6]. Portugal was ranked the highest
among Western European countries in terms of stroke
mortality [7], and available data suggests that stroke not only
continues to be the leading cause of death in this country
[8], but also that its incidence is comparatively higher (crude
annual incidence 3.05 and 2.69 per 1000 for rural and urban
populations, resp.; corresponding rates adjusted to European
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standard population 2.02 and 1.73) [9]. There is no definite
explanation for these facts, but a recent survey suggested
that a higher prevalence of AF in the Portuguese population
aged 40 and over, as compared to studies carried out in
other countries, combined with an underutilization of VKAs,
might contribute to these figures [10–12]. Furthermore, the
Stroke and Atrial Fibrillation Ensemble (SAFE) II study
suggested that, among patients with AF-associated stroke,
underutilization of VKAs (70% of the patients had an
indication for OAC, but less than 25% were anticoagulated)
is frequently attributed to inappropriate reasons, such as fear
of bleeding complications and low compliance [13].
Dabigatran was the first new oral anticoagulant approved
in Europe for stroke prevention in nonvalvular AF and be-
came available in Portugal earlier than in most other Euro-
pean countries. It seems reasonable to assume that its
widespread utilization may soon become a reality, not only in
hospital settings, but also in rural areas that lack laboratory
facilities and particularly among clinicians previously reluc-
tant in prescribing VKAs.
This paper is the joint effort of a panel of Portuguese
experts from different specialties and provides information
on the use of dabigatran, in anticipation of the challenges
that will come with increased usage. The authors discuss
the management of dabigatran-associated complications and
the different clinical scenarios a clinician may encounter in
patients treated with this new anticoagulant, underlining the
paucity of systematic data, particularly on the management
of recently reported hemorrhagic complications. Given the
lack of specific clinical evidence, some of the recommen-
dations below are based exclusively on the opinion of the
authors and are identified as Author’s Recommendations
(AR).
2. Questions
2.1. Should the Decision to Start Treatment with Dabigatran or
to Switch from VKAs to Dabigatran Be Restricted to Specialists
Managing Patients with Atrial Fibrillation? What Is the Role of
the General Practitioners (GPs)? AF is frequent in the general
population, its prevalence increases exponentially with age,
and it is responsible for up to 20% of all strokes [14]. Due
to the known limitations of VKAs, many patients with AF
at a moderate-to-high risk of stroke, and with an indication
for anticoagulation, are currently not treated [10]. For these
patients dabigatran represents a new window of opportunity.
As first-line clinicians in national health systems, GPs can
play a critical role not only in the diagnosis, but also in the
treatment of AF. This position can be strengthened by the
approval of new OACs, such as dabigatran, that has a better
efficacy/safety profile and a broader therapeutic window [1].
The prerequisite for dabigatran prescription is not so
much that the physician is a specialist or GP, but that he
is competent in AF management and knowledgeable of its
pharmacological treatment, dabigatran included.
When a GP diagnoses AF three issues must be addressed:
(1) rate and rhythm management,
(2) antithrombotic management,
(3) diagnosis of concomitant cardiac disease and, when
present, appropriate therapy [14].
In terms of antithrombotic therapy, recommendations
for its use should be based on the presence (or absence) of
risk factors and the risk of bleeding should also be taken
into account [14]. According to the 2010 European Society
of Cardiology (ESC) guidelines, the new CHA2DS2-VASc
stroke risk stratification scheme may have a better predictive
value when compared to the CHADS2 score [14]. As for
the risk of bleeding, the HAS-BLED risk stratification score
can be used for its determination [14]. With these results in
mind and with the objective of obtaining a positive clinical
benefit between prevention of thromboembolic events and
avoidance of hemorrhagic complications, the decision to
start OAC and to prescribe dabigatran or to switch from
VKAs to dabigatran can be taken by any physician (AR).
2.2. How to Start Dabigatran? How to Switch from VKAs
or Parenteral Anticoagulants to Dabigatran? Before starting
dabigatran, creatinine clearance (CrCl) must be evaluated
in all patients using the Cockcroft-Gault formula [15, 16].
In Europe, dabigatran is contraindicated in patients with
severe renal failure (CrCl < 30 mL/min) [17]. In the USA,
the FDA approved dabigatran 75 mg bid for patients with
a creatinine clearance of 15 to 30 mL/min [2]. A complete
blood count should also be performed, since anemia and
thrombocytopenia increase the risk of bleeding [4].
To switch from VKAs to dabigatran, physicians should
first stop VKA and obtain an international normalized
ratio (INR). If INR is below 2.0, dabigatran can be started
immediately; if INR is between 2.0 and 3.0, dabigatran
should be started in 2 days (AR). For patients with INR
above 3.0, a further INR should be obtained after 2 days and
dabigatran should be started as soon as the new INR is below
2.0, as stated above.
To switch from parenteral anticoagulants to dabigatran,
with intermittent therapy (low molecular weight heparin),
dabigatran should be given 0 to 2 hours before the time
the next dose would be due. With continuous treatment
(intravenous unfractionated heparin) dabigatran should be
given at the time of discontinuation [17].
When switching from a VKA to dabigatran, clinicians
should be aware that the benefits of dabigatran over warfarin
are influenced by the efficiency with which the INR is
controlled [18]. For all vascular events, nonhemorrhagic
events and mortality, advantages of dabigatran over warfarin
were greater at sites with poor INR control when compared
to sites with good INR control. Nevertheless, the benefits of
dabigatran 150 mg bid at reducing stroke or SE, dabigatran
110 mg bid at reducing major bleeding and both doses at
reducing intracranial bleeding were consistent irrespective of
the center’s quality of INR control.
2.3. After Starting Dabigatran, When Should a Follow-Up
Appointment Be Scheduled? Dabigatran does not require
routine laboratory monitoring. Nevertheless, it is important
to monitor adherence to therapy and eventual adverse events.
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Patients should be provided with a phone contact for
support.
The frequency of follow-up appointments in these
patients must consider multiple factors: presence of comor-
bidities; previous treatment with VKAs; age and respective
degree of autonomy; disease chronicity.
Patients should have a first visit within 3 to 6 months after
starting dabigatran and thereafter according to their medical
condition: in general, these patients should have biannual
visits (AR). In elderly patients (>75 years) or patients with
some degree of impaired renal function, quarterly visits are
recommended (AR).
Since dabigatran is eliminated primarily in urine and
since it is contraindicated in patients with severe renal
failure [17], renal function should be assessed in the first
appointment and every 6 months when mild-to-moderate
renal dysfunction is present or whenever a decline of renal
function is suspected.
2.4. How Can Adherence Be Checked and Improved? The
success of a clinical intervention depends not only on an
accurate diagnosis and appropriate treatment, but also on the
patient’s commitment to comply with the prescribed therapy.
Nonadherence is a major challenge for clinicians, especially
in elderly patients, and, as with other chronic diseases
(such as hypertension), AF patients should be monitored for
compliance [19].
In view of the short half-life of dabigatran (12 to 14 hours
after multiple doses) [3], no coagulation test can ascertain
long-term compliance. As such, the evaluation of continued
adherence must be clinically assessed.
To improve adherence, patient education should be rein-
forced. Prior to dabigatran prescription, clinicians should
explain to patients and caregivers what an anticoagulant is;
why it is being prescribed; what are its risks and benefits;
what adverse events can occur and how to identify and
deal with them. Patients and caregivers should be alerted of
the importance of immediately contacting the physician in
the event of bleeding or other adverse events and a special
emphasis should be given to the risks of noncompliance.
These measures should be complemented with educational
brochures and easy access to nonscheduled appointments.
For reassurance, prescribing physicians should provide a
phone contact to all patients starting dabigatran, especially
those switching over from VKAs.
Other healthcare providers should be aware that the
patient is anticoagulated, particularly if there is a possibility
of surgery. In this respect, patient alert cards are useful tools,
reinforcing patient adherence and providing other health
professionals with information on the prescribing drug.
2.5. How to Deal with Dyspepsia? Dyspepsia is a frequently
reported adverse event with drugs commonly prescribed
in primary care settings, such as NSAIDs or ticlopidine
[20]. In the RE-LY trial, dyspepsia was observed in 11.3%
and 11.8% of patients in the dabigatran arms and in
5.8% of patients in the warfarin arm [1]. Dabigatran-
related gastrointestinal (GI) symptoms were most commonly
of an esophageal/gastroesophageal reflux nature, typically
occurring soon after drug initiation with a mild-to-moderate
presentation and, in most cases, did not require drug
discontinuation. Patients with GI symptoms had a higher
risk of GI bleeding, irrespective of whether they were treated
with dabigatran or warfarin [21], but the rate of GI bleeding
was increased with dabigatran 150 mg bid versus warfarin
(annual rate 1.51% versus 1.02%, P = 0.007) [1].
It is important to inform patients that dyspepsia may
occur. The administration of dabigatran within meals
(breakfast and dinner) can mitigate this effect [22]. The value
of proton pump inhibitors in the management of dyspepsia,
in this specific scenario, is not yet clear. However, it is known
that a fifth of the patients enrolled in the RE-LY trial were on
pantoprazole and although the bioavailability of dabigatran
was reduced by about 12.5% in this subpopulation, a
negative impact on clinical outcomes was not observed
[17]. This data supports the use of pantoprazole for the
management of dabigatran related dyspepsia.
2.6. In Which Patients Treated with Dabigatran Should Coag-
ulation Be Monitored? The RE-LY trial showed that dabi-
gatran, when compared to warfarin, is an effective and
safe treatment that obviates the need for routine laboratory
monitoring.
The vast majority of patients will not benefit from
routine and scheduled coagulation monitoring. In patients
with an increased risk of bleeding, careful dose selection
is advised. If available, the lower 110 mg bid dose should
be used in patients aged at least 80 years; with high risk
of bleeding; in patients with concomitant dabigatran and
verapamil therapy [17]. In patients with moderate renal
impairment, close clinical surveillance is recommended,
including periodical assessment of renal function.
Only in exceptional situations may patients treated
with dabigatran require anticoagulation status assessment.
These situations are (1) cases of suspected overdose; (2)
patients presenting to the emergency departments with
acute bleeding, and (3) indication for urgent surgery
(see also Section 2.7).
2.7. How Can the Anticoagulant Effect of Dabigatran Be
Measured? There is a close correlation between plasma dabi-
gatran concentration and the degree of anticoagulant effect
evaluated by the ecarin clotting time (ECT) and thrombin
time (TT) [23]. To assess the risk of bleeding, qualitative tests
such as activated partial prothrombin time (aPTT) or TT
(other than the dabigatran calibrated Hemoclot thrombin
inhibitor assay) may be used [24]. For a quantitative
measurement of dabigatran plasma concentrations, only the
dabigatran calibrated Hemoclot thrombin inhibitor assay (a
diluted TT) is available [17].
Importantly, anticoagulant parameters depend on the
time when the blood sample is taken relative to the time when
the previous dose was given. A blood sample taken 2 hours
after dabigatran ingestion (∼peak level) will have different
(higher) result in all clotting tests compared to a blood
4 Thrombosis
sample taken 10 to 16 hours (trough level) after ingestion of
the same dose [25].
The following coagulation tests may be used to assess the
risk of bleeding.
(i) aPTT: this test may be useful in determining an excess
of anticoagulant activity, despite aPTT being less sensitive
to the activity of dabigatran above therapeutic levels [23].
An aPTT >80 seconds (2 to 3 × baseline value) at trough
is associated with a higher risk of bleeding [26]. A normal
aPTT (not exceeding the upper limit of normal) indicates
no clinically relevant anticoagulant effect of dabigatran. Most
patients with therapeutic dabigatran plasma concentrations
will have an aPTT ratio of about 1.5 to 2.0 (45 s to 65 s), at
trough [23, 24]. However, as previously stated, aPTT should
not be used as a quantitative measurement of dabigatran
plasma concentrations.
(ii) TT: the actual test measure will depend on the
coagulometer and the thrombin lot used for measurement.
(iii) Calibrated Hemoclot thrombin inhibitor assay (a
diluted TT): an assay calibrated with dabigatran standards,
to calculate dabigatran concentration [23]. In patients taking
dabigatran for stroke prevention in nonvalvular AF, a diluted
TT measure of >200 ng/mL of dabigatran plasma concen-
tration (approximately >65 seconds) prior to the next drug
intake (trough measure) is associated with a higher risk of
bleeding [24]. A normal diluted TT measurement indicates
no clinically relevant anticoagulant effect of dabigatran [26].
(iv) Prothrombin time and INR are unreliable in patients
on dabigatran and false positive INR elevations have been
reported [23, 27]. These tests should not be used (AR).
2.8. How Should Patients on Dabigatran with Major or Life-
Threatening Bleeding Events Be Managed? Even though life-
threatening bleeding events are expected to be lower with
dabigatran compared to VKA, it is advisable that hospitals
develop specific protocols for emergency situations.
Presently, there is no specific antidote for dabigatran.
However, it has recently been demonstrated that a specific
humanized antibody fragment may provide a selective and
rapid reversal of dabigatran activity. This antibody fragment
is currently under clinical development for human use [28].
In the event of hemorrhagic complications, dabigatran
must be discontinued and the source of bleeding investi-
gated. As dabigatran is primarily excreted in the urine, ade-
quate diuresis is needed and fluids should be administered
as tolerated (AR). Transfusions with fresh frozen plasma, red
blood cells, and fresh platelet concentrates may be consid-
ered, especially in cases where long-acting antiplatelet drugs
have been used. Reversal agents like recombinant factor
VIIa (rFVIIa) and activated or nonactivated prothrombin
complex concentrates (PCCs) may also be considered, as
suggested by experimental data [23, 29, 30]. Nevertheless,
their efficacy remains unproven in the clinical setting. In
a study with 12 healthy young volunteers who received
dabigatran 150 mg bid for two and a half days, a single
50 IU/Kg bolus of PCC did not reverse the aPTT, ECT, and
TT. However, no assessment of bleeding time or correlation
with bleeding was performed [31].
When considering a surgical resolution for the life-
threatening hemorrhagic complication, the risks of this
procedure must be very carefully considered. If all of the
above measures fail to control the bleeding, hemodialysis
may be useful for dabigatran removal, especially in patients
with renal impairment (see Section 2.11) [23, 32]. Hemop-
erfusion over a charcoal filter may also have some benefits
[33].
As an example of an official emergency room protocol,
the Pharmaceutical Management Agency of New Zealand
recently issued the following guidelines for management of
bleeding in patients treated with dabigatran [34].
(i) Mild bleeding: local hemostatic measures; delay next
dose of dabigatran or discontinue treatment, as
appropriate.
(ii) Moderate-to-severe bleeding: local measures; fluid
replacement; blood product transfusion; admin-
istration of antifibrinolytic agent for example,
tranexamic acid IV (15–30 mg/kg)±continuous infu-
sion (1 mg/kg/hr); consider Prothrombinex-VF 25–
50 IU/kg, and repeat if necessary with hematology
guidance.
(iii) Life-threatening bleeding: previous measures; rFVIIa
(100 mcg/kg by IV bolus), repeat if necessary with
hematology guidance; hemodialysis, especially if
renal failure is present.
2.9. How to Manage a Patient Treated with Dabigatran and
Referred for Urgent Surgery? Patients receiving antithrom-
botic therapy who undergo elective surgery or invasive
procedures are at increased risk of bleeding. Therefore,
these interventions may require temporary discontinuation
of antithrombotic agents, and dabigatran is not an exception.
Dabigatran should be discontinued 1 to 4 days prior to elec-
tive surgery, depending on the degree of renal impairment
and risk of bleeding (Table 1) [17].
If the surgery or invasive procedure cannot be delayed
to allow renal elimination of dabigatran and reversal of its
anticoagulant effect, the degree of anticoagulation should
be checked with the diluted TT assay (Hemoclot thrombin
inhibitor assay) or aPTT [20, 26]. In the event of a normal
diluted TT or aPTT (not exceeding the upper limit of
normal) then no clinically relevant anticoagulant effect of
dabigatran is present and surgery or invasive procedure can
proceed without delay. If plasma concentration of dabigatran
is >200 ng/mL or aPTT >80 seconds (2 to 3× baseline value)
and an urgent procedure with a high risk of bleeding is
necessary, reversal of the anticoagulant effect of dabigatran
with PCC or rFVIIa should be considered. If the blood
sample is not collected at trough, reference values for
coagulation tests are not currently available.
In the RE-LY study, patients receiving dabigatran were
more likely to have a surgery or invasive procedure within
24 hours of withholding OAC and did so with a substantially
lower risk of major bleeding than patients on warfarin
(relative risk reduction of 82% for dabigatran 110 mg bid and
56% for 150 mg bid) [35].
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Table 1: Guide to the discontinuation of dabigatran before elective
surgery or invasive procedure [17].
Renal function When to stop dabigatran before surgery
(CrCl mL/min) Standard risk of bleeding High risk of bleeding
>80 24 hours before 2 days before
>50 and ≤80 1-2 days before 2-3 days before
>30 and ≤50 2-3 days before 4 days before
When restarting dabigatran after surgery, clinicians
should be aware of the rapid onset of its anticoagulant
effect. Dabigatran can be resumed 24 to 72 hours after
surgery, depending on the bleeding risk of the patient and
procedure, as recommended for therapeutic heparin in the
ACCP Guidelines [36].
2.10. Is a Patient Treated with Dabigatran Suitable for Neurax-
ial Anesthesia? Neuraxial anesthesia comprises spinal (sub-
dural space anesthesia) and epidural block (epidural space
anesthesia) and is increasingly used in various types of
surgery for pain relief, in the perioperative or postoperative
periods [37].
The occurrence of spinal hematoma is a rare com-
plication of neuraxial anesthesia, but may result in irre-
versible neurological damage and its risk is increased with
antithrombotic therapy [38, 39]. Therefore, neuraxial anes-
thesia requires complete hemostatic function and dabigatran
should be temporarily discontinued before the procedure.
The timing of discontinuation should be adjusted in accor-
dance to the patient’s renal function and the procedure’s risk
of bleeding (Table 1).
Dabigatran may be initiated as soon as clinically indi-
cated and at least 6 hours after the removal of epidural
catheter [40].
2.11. Is Dialysis Efficient in Removing Dabigatran from Circu-
lation? Dabigatran is dialysable due to its relatively small
molecular size and low plasma protein binding (∼35%)
[23]. This concept is supported by small studies performed
in patients with a renal function ranging from normal to
severely depressed. One open-label study demonstrated that
the mean fraction of dabigatran removed by hemodialysis
was 62% at 2 hours and 68% at 4 hours [41]. Another
open-label study performed in patients with end-stage renal
disease showed that the mean fraction of dabigatran cleared
from plasma by high flow rate hemodialysis (400 mL/min)
was 54 to 68% at 4 hours [32].
In emergency situations, hemodialysis can be employed
to eliminate dabigatran and reduce its anticoagulant effect
[23].
2.12. Can a Patient Treated with Dabigatran Receive Dual
Antiplatelet Therapy (Aspirin Plus Clopidogrel)? Aspirin and/
or clopidogrel were used in 38.4% of patients during the RE-
LY study and increased the relative risk of major bleeding by
60%, but the risk was lower with dabigatran 110 mg bid when
compared to warfarin (HR 0.82, 95%CI: 0.67–1.00) [42].
Almost 5% of patients received dual antiplatelet therapy with
aspirin and clopidogrel [43]. In these patients, the relative
effects of both dabigatran 110 mg bid and 150 mg bid in
comparison to warfarin in terms of major bleeding risk were
consistent with the main trial results.
Adding aspirin to oral anticoagulation in patients with
stable vascular disease (coronary, carotid, or peripheral
arterial disease) does not reduce the risk of vascular events,
including myocardial infarction [14]. As such, concomitant
use of antiplatelets and oral anticoagulants should be
cautious and reserved to special indications such as acute
coronary syndromes or revascularization procedures. Dual
antiplatelet therapy should be restricted to patients receiving
coronary stenting. Implantation of drug eluting stents, which
require a period of 6 to 12 months of dual antiplatelet
therapy, should be avoided whenever possible [14]. The more
potent new P2Y12 inhibitors, prasugrel, and ticagrelor, which
have a higher bleeding risk than clopidogrel [44, 45], set new
challenges to the safety of combining OAC with antiplatelet
therapy.
In patients with nonvalvular atrial fibrillation and a
clear recommendation for oral anticoagulation (CHA2DS2-
VASc Score >1) and antiplatelet therapy, dabigatran is an
advantageous alternative to warfarin, particularly with the
110 mg bid dose [42, 43].
Whenever dual or triple antithrombotic therapy is used,
strict blood pressure control is strongly recommended [46].
2.13. How to Manage a Patient Treated with Dabigatran
and Admitted for an Acute Coronary Syndrome? Which
Antithrombotics Can Be Used If the Patient Is Referred for
Primary Angioplasty? Can Dabigatran Be Administered Safely
after an Acute Coronary Syndrome? In the RE-LY study, there
were specific recommendations for the management of acute
coronary syndromes (ACSs). This issue was also tackled in
the protocol of the RELY-ABLE trial, an extension of the
dabigatran treated patients that completed the RE-LY trial
(Table 2) [47].
ESC and ACC/AHA Guidelines recommend the use of
dual antiplatelet therapy (aspirin plus P2Y12 inhibitor) in
the setting of ACS [48–50] and this should also be applied
to the patient treated with dabigatran. Since guidelines
also recommend anticoagulation (heparin, fondaparinux,
or bivalirudin) in the acute phase, it seems reasonable to
temporarily discontinue dabigatran and start the recom-
mended anticoagulants at least 12 hours after the last dose of
dabigatran or as soon as the aPTT is <1.5 × baseline value.
If the patient is suitable for reperfusion therapy (ST-
segment elevation myocardial infarction and less than 12
hours of symptoms) primary percutaneous coronary inter-
vention (PCI) is preferable to fibrinolytic therapy. If primary
PCI is not available, fibrinolysis should only be administered
if aPTT is <1.5× baseline value and potential gains outweigh
the bleeding risks (AR).
Heparin should be administered during PCI according
to the usual target of activated clotting time (ACT). There
is a linear concentration-dependent increase in ACT with
dabigatran plasma concentrations of up to 250 ng/mL [23].
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Table 2: Recommendations for the management of acute coronary
syndromes in the RE-LY and RELY-ABLE studies [47].
(1) Dabigatran should be temporarily discontinued
(2) Aspirin, clopidogrel and glycoprotein IIb/IIIa inhibitors may be
administered according to usual clinical practice
(3) Heparin can be started 12 or more hours after the last dose of
dabigatran or as soon as the aPTT is <1.5 × baseline value
(4) Reperfusion with primary PCI is preferable to fibrinolysis
(5) During PCI the ACT should be measured and heparin
administered as needed according to usual practice
Dabigatran can be restarted after the discontinuation of
heparin, which generally occurs after coronary revasculariza-
tion or after at least 48 hours of heparin therapy.
In the RE-LY trial, the annual rate of myocardial
infarction (MI) was slightly higher in the dabigatran groups
(0.82%/year for 110 mg and 0.81%/year for 150 mg) when
compared with the warfarin group (0.64%/year) [51, 52].
This result may represent a play of chance or a more protec-
tive effect of warfarin against MI in patients with AF [53].
Nevertheless, in the RE-LY trial, this potential advantage
of warfarin was exceeded by the benefit of dabigatran on
cerebrovascular events, as reflected in the lower annual rate
of vascular mortality observed in the dabigatran groups [1].
One meta-analysis of 7 trials found an increased risk of
MI and ACS associated with dabigatran [54], but in clinical
trials of primary prevention of venous thromboembolism, in
patients undergoing major orthopedic surgery, no increase
in ACS was detected in patients treated with dabigatran
when compared to those treated with enoxaparin [55]. In
the RE-LY platelet function substudy, no evidence of platelet
activation was observed in the group of patients with AF
receiving dabigatran when compared to warfarin [56].
2.14. How to Manage Anticoagulant Therapy in a Patient
Treated with Dabigatran and Submitted to Percutaneous Abla-
tion of AF? In a recent study, administration of dabigatran to
123 consecutive patients after percutaneous ablation of AF
was found to be well tolerated and safe in terms of bleeding
complications and thromboembolic events, leading to the
conclusion that dabigatran could be a good alternative to
warfarin in this context [57].
In this study, periprocedural anticoagulation was based
on a predetermined algorithm. Patients on dabigatran prior
to AF ablation stopped this drug 36 hours before the
procedure if estimated glomerular filtration rate (GFR) was
>60 mL/min, 48 hours before the procedure if GFR was 40 to
60 mL/min, and 60 hours before the procedure if estimated
GFR was <40 mL/min. Patients receiving dabigatran before
ablation did not receive preprocedural enoxaparin.
Intraprocedural anticoagulation consisted on a weight-
based bolus of unfractionated heparin administered when
the transseptal sheath entered the left atrium, followed by
a 1,000 units/hour infusion running through the transseptal
sheath. Additional heparin administration depended on the
ACT, targeted at 225 seconds. At the end of the procedure,
heparin was reversed with protamine and all sheaths were
removed.
After ablation patients received two doses of enoxaparin
(0.5 mg/kg), the first one immediately at the end of the
procedure and the second 12 hours later. Dabigatran was
started 10 hours after the last enoxaparin dose (22 hours
after the procedure) at a dose of 150 mg bid if the estimated
GFR was >30 mL/min and 75 mg bid if the estimated GFR
was between 15 and 30 mL/min (in Europe, the 75 mg bid
dose is not approved for stroke prevention in patients with
nonvalvular AF). Patients with a GFR <15 mL/min were not
considered for dabigatran.
Dabigatran was maintained for at least 30 days after
ablation. No postablation strokes, transient ischemic attacks,
or systemic thromboembolic events were reported [57].
The Dabigatran for Peri Procedural Anticoagulation
During Radiofrequency Ablation of Atrial Fibrillation (DAP-
PAR AF) trial, a prospective, open-label study, will start in a
near future. In this trial, periprocedural anticoagulation will
be managed in a similar way to that which is described in the
previous study and this trial’s primary outcome will be the
incidence of periprocedural major bleeding complications
[58].
2.15. How to Manage Cardioversion in a Patient Treated with
Dabigatran? Cardioversion to sinus rhythm (pharmacolog-
ical or electrical) can be safely considered in AF patients
treated with dabigatran. According to the ESC guidelines
[14], in patients with AF of 48 h or longer duration (or
AF of unknown duration) undergoing cardioversion, oral
anticoagulants should be given for at least 3 weeks prior and
4 weeks after cardioversion.
This recommendation is also valid for dabigatran.
Despite the fact that with dabigatran effective anticoagu-
lation is obtained within 2 hours of administration, the
possibility of a thrombus being already present in the left
atrial appendage must be considered.
There is no prospective data on the safety of cardiover-
sion under dabigatran treatment, but a post hoc analysis
of the RE-LY trial revealed a low and comparable rate of
cardioversion-related strokes in patients treated with dabiga-
tran versus VKA [59]. In this study, the largest cardioversion
study to date and the first evaluating dabigatran in this
setting, more dabigatran patients underwent prior trans-
esophageal echocardiography (TEE) (25.5% for dabigatran
110 mg, 24.1% for dabigatran 150 mg, and 13.3% for
warfarin, P < 0.0001 for comparisons between dabigatran
and warfarin) and although the prevalence of left atrial
thrombus was not significantly higher in the dabigatran
patients (1.8% for dabigatran 110 mg, 1.2% for dabigatran
150 mg, and 1.1% for warfarin, P = NS for comparisons
between dabigatran and warfarin), it may still be prudent
to recommended a TEE before a planned cardioversion in
patients taking dabigatran.
It is important to point out that the routinely performed
INR test, prior to cardioversion, is of no use in patients
treated with dabigatran and noteworthy that the dabigatran-
specific coagulation assay (diluted assay) will inform if the
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patient took dabigatran that particular morning, but gives
no information on treatment compliance over the preceding
3 week period. Therefore, compliance of drug intake in the
preceding 3 to 4 weeks should be specifically inquired and
documented in the patient’s file.
Finally, it is also important to recall that long-term
anticoagulation is required for patients with a high throm-
boembolic risk, even if sinus rhythm is restored [14].
2.16. Is It Safe to Perform Thrombolysis for an Acute Ischemic
Stroke in a Patient Treated with Dabigatran? Despite the fact
that there are no evidence-based data to answer this question,
thrombolytic therapy is not recommended for anticoag-
ulated patients with dabigatran [17]. There is only one
reported case of thrombolytic treatment with intravenous rt-
PA performed just below 4.5 h after the onset of symptoms
and 7 hours after the last administration of dabigatran
(aPTT 34.8 seconds, normal range 22.2–34.4 seconds; TT
not reported) [60]. In this case, no hemorrhagic complica-
tions were observed. The Interventional Management Stroke
(IMS) III trial proposed that administration of rt-PA or
endovascular treatment could be considered 48 h after the
last intake of dabigatran or within 48 h of last intake with
a normal aPTT [61]. Future studies are needed in order to
answer this question, until then the use of fibrinolytic agents
for the treatment of acute ischemic stroke can probably
be considered if the patient presents with a diluted TT or
aPTT not exceeding the upper limit of normal, according
to the local reference range, but careful evaluation of patient
eligibility is strongly encouraged.
2.17. In a Patient with AF and an Acute Ischemic Stroke, or
Transient Ischemic Attack, When Should Therapy with Dabi-
gatran Be Initiated? A substudy of the RE-LY trial showed
that there was no increase in adverse events, including
intracranial bleeding, with the two doses of dabigatran when
compared to warfarin, between patients with and without
previous stroke or transient ischemic attack [62]. Never-
theless, this trial excluded patients with transient ischemic
attack or ischemic stroke in the two weeks before enrollment.
Thus, while initiation of dabigatran seems safe after the first
two weeks, further data on earlier initiation of dabigatran
after stroke or transient ischemic attack is needed. However,
it is important to underline that, in these settings, data
concerning initiation of other anticoagulant drugs, including
VKAs, is also lacking. An ongoing observational multicenter
study, the Risk of early stroke recurrence in patients with
Atrial Fibrillation (RAF) study, is currently evaluating timing
of initiation of different anticoagulant drugs in patients
with transient ischemic attack or acute ischemic stroke and
AF (Paciaroni et al., unpublished data, 2011). Early intro-
duction of dabigatran in transient ischemic attacks or minor
ischemic stroke cases seems attractive, in view of its rapid
anticoagulant action, and is probably feasible, but more data
is needed in order to identify the optimal time for treatment
initiation. Delaying introduction of anticoagulant therapy
in patients with extensive ischemic lesions, as proposed by
current guidelines [63], should also be advocated in the case
of dabigatran, to avoid hemorrhagic transformation.
2.18. How Should Intracranial Bleeding Be Managed in a
Patient Treated with Dabigatran? Fewer intracranial hemor-
rhagic events are expected in patients under treatment with
dabigatran than in patients treated with warfarin. In the
RE-LY trial, in comparison with warfarin treatment, there
was a marked reduction of intracranial bleeding with both
doses of dabigatran (69% reduction with dabigatran 110 mg
bid and 60% reduction with dabigatran 150 mg bid, P <
0.001 for comparisons between dabigatran and warfarin) [1].
Nevertheless, it is important to understand how to manage
these situations in case they do occur.
As there is no antidote for dabigatran, currently avail-
able, supportive treatment in order to stop bleeding is
the mainstay of management of intracranial hemorrhagic
events. Dabigatran should be stopped immediately and
symptomatic treatment should be initiated. Further attitudes
should be individualized according to the severity of the
hemorrhage [64, 65], and measures described in Section 2.8
should be taken into account.
3. Conclusion
The questions answered in this paper represent some of the
relevant issues clinicians will face when asked to manage
nonvalvular AF patients treated with dabigatran. Informa-
tion about these and other management issues should be
easily and widely available, in order to improve correct
patient and drug dosage selection, taking into account
variables such as age, renal function, and comorbidities.
“Real-world” experience with dabigatran and further
evidence from ongoing clinical trials will dictate the need for
adjustments to the recommendations in this paper.
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